Commure, Inc.☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Commure, Inc. is one of 2138 Healthtech companies tracked from MOUNTAIN VIEW. By capital raised it ranks among the largest (ahead of 100% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Commure is reshaping the healthcare landscape with AI-powered solutions that streamline operations, reduce costs, and improve patient and provider experiences.

Commure is reshaping the healthcare landscape with AI-powered solutions that streamline operations, reduce costs, and improve patient and provider experiences. Explore insights, customer stories, and expert perspectives across clinical, revenue, and operational workflows. Insights for clinical leaders, physicians, nurses, and care teams focused on improving care delivery, reducing administrative burden, and enhancing the clinical experience. Perspectives for healthcare leaders on strategy, operational transformation, digital innovation, and the future of care delivery. Resources for finance and revenue cycle leaders on revenue performance, operational efficiency, and the financial impact of healthcare technology. Complexity is killing healthcare - it’s hurting patients, providers, and administrators who work day-in day-out to keep us healthy. At Commure, we develop cutting-edge technology with leading health systems to simplify every step in the delivery of healthcare. Providers no longer have to fight mountains of documentation, administrators aren’t chasing endless denial queues, and security teams have the infrastructure they need to manage staff safety. We believe that healthca

Trades publicly as Company.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Growth/Late — a round over $400M). Valuation is modeled from stage benchmarks scaled by the healthtech sector profile. Directional, not a quoted figure.

Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 100% of sector peers (real $). Modeled value above 65% of peers (estimate).

A tighter cohort than the sector chart above — only companies at the same stage (Growth/Late) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful.

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Seed$2.0M2017-09-19
   • First recorded raise — entered as Seed.
   • 1 investor on this round.
2. Series A$10.0M2017-12-27
   • Came back fast: 3 mo vs the ~14 mo sector norm.
   • Round 5.0× larger than the prior — scaling up.
   • 1 investor on this round.
3. Series B$24.8M2018-06-05
   • Came back fast: 5 mo vs the ~14 mo sector norm.
   • Round 2.5× larger than the prior — scaling up.
   • 4 investors on this round.
4. Series B$27.0M2019-04-12
   • Raised 10 mo later, in step with the ~14 mo sector norm.
   • Round roughly the size of the prior one.
   • 5 investors on this round.
5. Series B$3.3M2020-09-01
   • Raised 17 mo later, in step with the ~14 mo sector norm.
   • Round 8.2× smaller than the prior — bridge or down round.
   • 1 investor on this round.
6. Series D+$210.2M2020-11-19
   • Came back fast: 3 mo vs the ~14 mo sector norm.
   • Round 63.8× larger than the prior — scaling up.
   • 11 investors on this round.
7. Series D+$149.0M2021-09-01
   • Raised 9 mo later, in step with the ~14 mo sector norm.
   • Round 1.4× smaller than the prior — bridge or down round.
   • 1 investor on this round.
8. Series D+$150.0M2021-09-13
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round roughly the size of the prior one.
   • 3 investors on this round.
9. Series D+$3.8M2021-12-31
   • Came back fast: 4 mo vs the ~14 mo sector norm.
   • Round 40.0× smaller than the prior — bridge or down round.
   • 1 investor on this round.
10. Series D+$38.7M2023-09-22
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 10.3× larger than the prior — scaling up.
    • 38 investors on this round.
11. Growth/Late$1.3B2023-10-03
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 33.2× larger than the prior — scaling up.
    • 56 investors on this round.
12. Growth/Late$4.5M2024-05-23
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 288.3× smaller than the prior — bridge or down round.
    • 1 investor on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

Commure, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Discovered from commure — the partnerships, launches, hiring and press it publishes about itself. Evidence the company is alive and what it is doing now, not financial data.

• UpdateHealthcare AI Deployed at Unparalleled Scale2026-05-19
• UpdateAn AI-Native Platform for the Next Era of Healthcare ‍ ‍2026-05-19
• UpdateAbout Athelas/Commure2026-05-19
• UpdateMedia Contact2026-05-19
• AwardCommure Named “Overall NLP Company of the Year” in 2026 AI Breakthrough Awards
• FundingCommure Raises $70M at $7B Valuation to Transform Healthcare Operations Using AI
• PartnershipWillis Knighton Health Selects Commure as Enterprise Ambient Scribe AI Partner
• ProductCommure Introduces Dictation: AI-Powered Clinical Voice, Now at the Cursor

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Commure, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Commure, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.